ISPRHIGH SIGNALFINANCIAL10-K

ISPR experienced a catastrophic 98% decline in stockholders' equity to just $605K while operating losses nearly tripled to $37.8M, indicating severe financial distress.

The company is facing an acute liquidity crisis with stockholders' equity collapsing from $34.5M to $605K, suggesting the business is on the verge of insolvency. Combined with massively widening operating losses and declining cash reserves, ISPR appears to be burning through its remaining capital at an unsustainable rate.

Comparing 2025-09-15 vs 2024-09-27View on EDGAR →
FINANCIAL ANALYSIS

ISPR's financial position deteriorated dramatically across nearly all metrics, with stockholders' equity plummeting 98% to just $605K while operating losses nearly tripled from $13.9M to $37.8M. Cash and cash equivalents declined 31% to $24.4M and accounts receivable fell 34%, indicating both operational struggles and liquidity pressures. The only positive development was improved operating cash flow performance (-$7.4M vs -$18.3M), though this appears insufficient given the magnitude of losses and the company's critically weakened balance sheet position.

FINANCIAL STATEMENT CHANGES
Dividends Paid
Cash Flow
+616%
$470K→$3.4M

Dividend payments increased 616% — management confidence in sustained cash generation.

Operating Income
P&L
-172.4%
-$13.9M→-$37.8M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Net Income
P&L
-165.7%
-$14.8M→-$39.2M

Net income declined 165.7% — review whether driven by operations, interest costs, or non-recurring items.

Stockholders Equity
Balance Sheet
-98.2%
$34.5M→$605K

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Operating Cash Flow
Cash Flow
+59.7%
-$18.3M→-$7.4M

Operating cash flow surged 59.7% — exceptional cash generation, highest quality earnings signal.

R&D Expense
P&L
-53.4%
$779K→$363K

R&D spending cut 53.4% — could signal cost discipline or concerning reduction in innovation investment.

Capital Expenditure
Cash Flow
-44.1%
$2.0M→$1.1M

Capex reduced 44.1% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Accounts Receivable
Balance Sheet
-33.6%
$59.7M→$39.7M

Receivables declined — improved collection efficiency or conservative revenue recognition.

Total Deposits
Balance Sheet
-31%
$34.7M→$23.9M

Deposits declined 31% — significant outflows warrant immediate investigation into funding stability.

Cash & Equivalents
Balance Sheet
-30.6%
$35.1M→$24.4M

Cash declined 30.6% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

LANGUAGE CHANGES
NEW — 2025-09-15
PRIOR — 2024-09-27
ADDED
As of September 15, 2025, there were 57,277,874 shares of the registrant s common stock, par value $0.0001 per share (the Common Stock ), outstanding.
All statements contained in this Annual Report and any documents we incorporate by reference, other than statements of historical facts, are forward-looking statements including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth.
These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.
The words may, will, could, would, should, believes, expects, anticipates, estimates, intends, plans, potential and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements, although not all forward-looking statements contain these identifying words.
We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our business, financial condition and operating results.
+7 more — sign up free →
REMOVED
As of September 26, 2024, there were 56,641,041 shares of the registrant s common stock, par value $0.0001 per share (the Common Stock ), outstanding.
Such statements may include, without limitation, statements with respect to the Company s plans, objectives, projections, expectations and intentions and other statements identified by words such as may, will, could, would, should, believes, expects, anticipates, estimates, intends, plans, potential or similar expressions.
These statements are based upon the current beliefs and expectations of the Company s management and do not constitute guarantees of future performance.
Actual results (including, without limitation, the actual timing for and results of the PMTAs described herein, and other FDA review of the Company s products in development), levels of activity, performance or achievements expressed or implied may differ significantly from those set forth in the forward-looking statements.
We do not undertake any obligation to release publicly any revisions to these forward-looking statements to reflect events or circumstances after the date of this Form 10-K or to reflect the occurrence of unanticipated events, except as may be required under applicable U.S.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →